Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01414920 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 368
- Enrollment target
NCT01414920 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 368 participants.
The verdict
NCT01414920, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 368 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), in combination with sitagliptin QD in participants with type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG TAK-875
- DRUG TAK-875 and Sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 368 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01414920
The ClinicalTrials.gov registry entry for NCT01414920 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 368 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01414920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01414920 about?
NCT01414920 is a clinical study titled "Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus". The purpose of this study is to determine the efficacy and safety of TAK-875, once daily (QD), in combination with sitagliptin QD in participants with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT01414920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 368 participants. The study started on 2011-08. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01414920?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), TAK-875 (DRUG), TAK-875 and Sitagliptin (DRUG).
Who is sponsoring clinical trial NCT01414920?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.